Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations

GA Ricaurte, AL Martello, JL Katz and MB Martello

Department of Neurology, Francis Scott Key Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

The purpose of this study was to assess the duration of (+-)-3,4- methylenedioxymethamphetamine's (MDMA's) effects on serotonin containing neurons in nonhuman primates. Fifteen squirrel monkeys were used: three served as controls, 12 received MDMA s.c. at a dose of 5 mg/kg twice daily for 4 consecutive days. Two weeks, 10 weeks, 8 months and 18 months after drug treatment, groups (n = 3) of MDMA-treated monkeys, along with controls, were examined for regional brain content of serotonin and 5-hydroxyindoleacetic acid, and for the number of [3H] paroxetine-labeled serotonin uptake sites. Two weeks after MDMA treatment, monkeys showed profound reductions in all three serotonergic presynaptic markers. By 10 weeks, there was evidence of partial recovery in some brain regions (e.g., hippocampus, caudate nucleus, frontal cortex). However, by 18 months, it was evident that recovery did not continue, as serotonergic deficits returned to the level of severity observed 2 weeks after MDMA treatment. This was the case in all brain regions examined except the thalamus and hypothalamus. In the thalamus, the level of serotonin increased to 63% of control, whereas that of 5-hydroxyindoleacetic acid recovered completely. In the hypothalamus, concentrations of serotonin and 5-hydroxyindoleacetic acid were 140 and 187% of control, respectively. These results suggest that MDMA produces lasting effects on serotonergic neurons in nonhuman primates, with most brain regions showing evidence of persistent denervation and some showing signs of reinnervation (thalamus) or possibly even hyperinnervation (hypothalamus). The morphological and functional correlates of these enduring neurochemical changes in the MDMA-treated primate remain to be delineated.

Volume 261, Issue 2, pp. 616-622, 05/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. M. L. de Win, G. Jager, J. Booij, L. Reneman, T. Schilt, C. Lavini, S. D. Olabarriaga, N. F. Ramsey, G. J. d. Heeten, and W. van den Brink Neurotoxic effects of ecstasy on the thalamus The British Journal of Psychiatry, October 1, 2008; 193(4): 289 - 296. [Abstract] [Full Text] [PDF]

				T. Schilt, M. M. L. de Win, M. Koeter, G. Jager, D. J. Korf, W. van den Brink, and B. Schmand Cognition in Novice Ecstasy Users With Minimal Exposure to Other Drugs: A Prospective Cohort Study Arch Gen Psychiatry, June 1, 2007; 64(6): 728 - 736. [Abstract] [Full Text] [PDF]

				C. Guillot and D. Greenway Recreational ecstasy use and depression J Psychopharmacol, May 1, 2006; 20(3): 411 - 416. [Abstract] [PDF]

				J. Daumann, B. Till, T. Fischermann, M. Rezk, and E. Gouzoulis-Mayfrank Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study J Psychopharmacol, March 1, 2006; 20(2): 236 - 244. [Abstract] [PDF]

				C. Pifl, G. Nagy, S. Berenyi, A. Kattinger, H. Reither, and S. Antus Pharmacological Characterization of Ecstasy Synthesis Byproducts with Recombinant Human Monoamine Transporters J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 346 - 354. [Abstract] [Full Text] [PDF]

				T. Xie, L. Tong, U. D. McCann, J. Yuan, K. G. Becker, A. O. Mechan, C. Cheadle, D. M. Donovan, and G. A. Ricaurte Identification and Characterization of Metallothionein-1 and -2 Gene Expression in the Context of ({+/-})3,4-Methylenedioxymethamphetamine-Induced Toxicity to Brain Dopaminergic Neurons J. Neurosci., August 11, 2004; 24(32): 7043 - 7050. [Abstract] [Full Text] [PDF]

				A. R. Green, A. O. Mechan, J. M. Elliott, E. O'Shea, and M. I. Colado The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Pharmacol. Rev., September 1, 2003; 55(3): 463 - 508. [Abstract] [Full Text] [PDF]

				Z. Szabo, U. D. McCann, A. A. Wilson, U. Scheffel, T. Owonikoko, W. B. Mathews, H. T. Ravert, J. Hilton, R. F. Dannals, and G. A. Ricaurte Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions J. Nucl. Med., May 1, 2002; 43(5): 678 - 692. [Abstract] [Full Text] [PDF]

				L. Reneman, C. B. L. M. Majoie, H. Flick, and G. J. den Heeten Reduced N-Acetylaspartate Levels in the Frontal Cortex of 3,4-Methylenedioxymethamphetamine (Ecstasy) Users: Preliminary Results AJNR Am. J. Neuroradiol., February 1, 2002; 23(2): 231 - 237. [Abstract] [Full Text] [PDF]

				T. Xie, L. Tong, T. Barrett, J. Yuan, G. Hatzidimitriou, U. D. McCann, K. G. Becker, D. M. Donovan, and G. A. Ricaurte Changes in Gene Expression Linked to Methamphetamine-Induced Dopaminergic Neurotoxicity J. Neurosci., January 1, 2002; 22(1): 274 - 283. [Abstract] [Full Text] [PDF]

				L. Reneman, J. Lavalaye, B. Schmand, F. A. de Wolff, W. van den Brink, G. J. den Heeten, and J. Booij Cortical Serotonin Transporter Density and Verbal Memory in Individuals Who Stopped Using 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy"): Preliminary Findings Arch Gen Psychiatry, October 1, 2001; 58(10): 901 - 906. [Abstract] [Full Text] [PDF]

				L. Reneman, C. B. L. M. Majoie, J. B. A. Habraken, and G. J. den Heeten Effects of Ecstasy (MDMA) on the Brain in Abstinent Users: Initial Observations with Diffusion and Perfusion MR Imaging Radiology, September 1, 2001; 220(3): 611 - 617. [Abstract] [Full Text] [PDF]

				H. W. Broening, L. L. Morford, S. L. Inman-Wood, M. Fukumura, and C. V. Vorhees 3,4-Methylenedioxymethamphetamine (Ecstasy)-Induced Learning and Memory Impairments Depend on the Age of Exposure during Early Development J. Neurosci., May 1, 2001; 21(9): 3228 - 3235. [Abstract] [Full Text] [PDF]

				T. Xie, U. D. McCann, S. Kim, J. Yuan, and G. A. Ricaurte Effect of Temperature on Dopamine Transporter Function and Intracellular Accumulation of Methamphetamine: Implications for Methamphetamine-Induced Dopaminergic Neurotoxicity J. Neurosci., October 15, 2000; 20(20): 7838 - 7845. [Abstract] [Full Text] [PDF]

				K. E. Sabol, J. B. Richards, and K. Yung The Effects of High-Dose Methamphetamine in the Aging Rat: Differential Reinforcement of Low-Rate 72-s Schedule Behavior and Neurochemistry J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 850 - 863. [Abstract] [Full Text]

				E. Gouzoulis-Mayfrank, J. Daumann, F. Tuchtenhagen, S. Pelz, S. Becker, H.-J. Kunert, B. Fimm, and H. Sass Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) J. Neurol. Neurosurg. Psychiatry, June 1, 2000; 68(6): 719 - 725. [Abstract] [Full Text] [PDF]

				W. E. Lyons, L. A. Mamounas, G. A. Ricaurte, V. Coppola, S. W. Reid, S. H. Bora, C. Wihler, V. E. Koliatsos, and L. Tessarollo Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities PNAS, December 21, 1999; 96(26): 15239 - 15244. [Abstract] [Full Text] [PDF]

				G. Hatzidimitriou, U. D. McCann, and G. A. Ricaurte Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery J. Neurosci., June 15, 1999; 19(12): 5096 - 5107. [Abstract] [Full Text] [PDF]

				A.C. Parrott, A. Lees, N.J. Garnham, M. Jones, and K. Wesnes Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits J Psychopharmacol, January 1, 1998; 12(1): 79 - 83. [Abstract] [PDF]

				V. Villemagne, J. Yuan, D. F. Wong, R. F. Dannals, G. Hatzidimitriou, W. B. Mathews, H. T. Ravert, J. Musachio, U. D. McCann, and G. A. Ricaurte Brain Dopamine Neurotoxicity in Baboons Treated with Doses of Methamphetamine Comparable to Those Recreationally Abused by Humans: Evidence from [11C]WIN-35,428 Positron Emission Tomography Studies and Direct In Vitro Determinations J. Neurosci., January 1, 1998; 18(1): 419 - 427. [Abstract] [Full Text] [PDF]

				U. D. McCann, K. A. Lowe, and G. A. Ricaurte REVIEW {blacksquare} : Long-lasting Effects of Recreational Drugs of Abuse on the Central Nervous System Neuroscientist, November 1, 1997; 3(6): 399 - 411. [Abstract] [PDF]

				U. D. Mccann, J. Yuan, G. Hatzidimitriou, and G. A. Ricaurte J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1487 - 1498. [Abstract]